Zevra Therapeutics
ZVRA
27 hedge funds and large institutions have $3.09M invested in Zevra Therapeutics in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 12 closing their positions.
29% less funds holding
Funds holding: 38 → 27 (-11)
47% less capital invested
Capital invested by funds: $5.86M → $3.09M (-$2.77M)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$20.7K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$13.2K |
| 3 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
+$12.5K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.34K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$500 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$90K |
| 2 |
DM
Deerfield Management
New York
|
-$86.6K |
| 3 |
RFN
RDA Financial Network
Akron,
Iowa
|
-$33.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19.9K |
| 5 |
GM
GeoWealth Management
Chicago,
Illinois
|
-$18K |
ZVRA Hedge Fund Activity: Q4 2019 in Review
27 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q4 2019, worth a combined $3.09M — down 47% from $5.86M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ZVRA and 1 opened new positions — a net loss of 11 holders — while 9 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $20.7K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $90K sold.
- 27 institutional investors held Zevra Therapeutics (ZVRA) as of Q4 2019, down from 38 in Q3 2019.
- Funds reported $3.09M of Zevra Therapeutics stock for Q4 2019, down 47% quarter-over-quarter.
- 1 fund opened new Zevra Therapeutics positions in Q4 2019 and 12 closed out, a net change of -11 holders.
- The largest Zevra Therapeutics buyer in Q4 2019 was Citadel Advisors, an estimated $20.7K added.
- The largest Zevra Therapeutics seller in Q4 2019 was Bridgeway Capital Management, an estimated $90K sold.
Based on aggregated 13F filings for Q4 2019.